Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:anticoagulant
low molecular weight heparin |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvedBy |
gptkb:Canada
gptkb:European_Union gptkb:United_Kingdom |
| gptkbp:ATCCode |
B01AB10
|
| gptkbp:brand |
Innohep
|
| gptkbp:CASNumber |
9045-49-4
|
| gptkbp:contraindication |
history of heparin-induced thrombocytopenia
active major bleeding |
| gptkbp:discoveredBy |
gptkb:Leo_Pharma
|
| gptkbp:eliminationHalfLife |
3.4 hours
|
| gptkbp:excretion |
gptkb:kidney
|
| https://www.w3.org/2000/01/rdf-schema#label |
tinzaparin
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits factor Xa and IIa
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C
|
| gptkbp:PubChem_CID |
DB08813
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
bleeding
thrombocytopenia |
| gptkbp:UNII |
O5I7G5B19G
|
| gptkbp:usedFor |
treatment of deep vein thrombosis
treatment of pulmonary embolism prevention of deep vein thrombosis |
| gptkbp:bfsParent |
gptkb:heparin
|
| gptkbp:bfsLayer |
6
|